
More needs to be done in renal cancer
Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier
Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier
In the Patient Advocacy Track, the importance and challenges around placing the patient at the centre of clinical trials
Recent evidence suggests a role of the microbiome in cancer pathogenesis and as a potential therapeutic target, but it is still early days
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
Data presented at the ESMO Gynaecological Cancers Congress 2022 confirm the vital role of national screening programmes and highlight the importance of local access
The advent of PARP inhibitors, an increased use of laparoscopy for patient selection and a more prominent role of PROs have been facilitated by international collaborations
In this era of precision medicine, affordable profiling is essential
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022
Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.